Two Sigma Securities LLC Raises Stock Position in Boston Scientific Corporation $BSX

Two Sigma Securities LLC lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 261.3% during the 2nd quarter, Holdings Channel.com reports. The fund owned 98,200 shares of the medical equipment provider’s stock after buying an additional 71,019 shares during the period. Two Sigma Securities LLC’s holdings in Boston Scientific were worth $4,191,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Renaissance Group LLC purchased a new stake in shares of Boston Scientific in the 4th quarter worth about $28,064,000. Perigon Wealth Management LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at about $883,000. Y Intercept Hong Kong Ltd increased its holdings in Boston Scientific by 148.8% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after acquiring an additional 670,060 shares in the last quarter. Wealthfront Advisers LLC purchased a new position in Boston Scientific during the 2nd quarter valued at about $3,253,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab raised its position in Boston Scientific by 9.9% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after acquiring an additional 28,961 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $46.82 on Monday. The company has a market cap of $67.85 billion, a P/E ratio of 18.96, a P/E/G ratio of 1.02 and a beta of 0.56. The business has a fifty day simple moving average of $46.56 and a 200-day simple moving average of $56.53. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the prior year, the business posted $0.75 earnings per share. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has authorized a stock repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

Several analysts have recently commented on BSX shares. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Citigroup cut their price objective on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Mizuho reduced their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Zacks Research cut Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Finally, The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a research report on Thursday, May 28th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $71.62.

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney acquired 186,240 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 194,522 shares of company stock worth $9,385,210 in the last three months. Company insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.